AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting riskPopularity #4,431

VTGN · NASDAQ · Biotechnology

VistaGen Therapeutics (VTGN)

Develops intranasal pherine candidates for psychiatric, women's-health, and cancer-supportive-care conditions.

$0.3778

vs last close+0.13 (+50.28%)

Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data
Benzinga2h agoClinical
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
GlobeNewsWireSep 22
Vistagen to Present at Psych Congress 2026
GlobeNewsWireSep 10Clinical
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
GlobeNewsWireAug 14
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
GlobeNewsWireAug 6
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
GlobeNewsWireAug 4
Vistagen Appoints Douglas J. Williamson to its Board of Directors
GlobeNewsWireJul 31
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Seeking AlphaJun 30
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
BenzingaJun 30
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Business WireJun 30
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Business WireJun 15
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Business WireJun 9
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
GuruFocusJun 1
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
PRNewsWireJun 1
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
Business WireMay 19
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Business WireMay 12
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Business WireMay 8
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
GlobeNewsWireApr 29
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop
PRNewsWireApr 28
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
Business WireApr 22
VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average – Should You Sell?
Defense WorldApr 11
VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Above 50-Day Moving Average – Here’s Why
Defense WorldMar 20
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
GlobeNewsWireMar 17
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
GlobeNewsWireMar 16